跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

Why AI-Designed Drugs Haven't Changed Medicine Yet

1The Promise and the Puzzle2From Molecule to Medicine: The Journey a Drug Must Survive3Where AI Actually Helps in the Pipeline4The Prediction Gap: When a Good Molecule Meets a Real Body5The Long, Expensive Road of Clinical Trials6Money, Incentives, and the Business of Drug Development7Regulation, Evidence, and Trust8What Would Have to Change
Regulation, Evidence, and Trust

What Counts as Proof

1 / 4
The key idea here is that approval is not a judgment about how clever a drug is. It is a judgment about evidence, and the evidence has to come from people. A model can suggest a molecule, but it cannot show that a patient benefits. The marker example makes this concrete: lowering a protein that looks relevant is not the same as helping someone live longer or feel better. The protein might just be a bystander. And notice who carries the burden — the developer has to prove benefit, not the regulator prove harm. That asymmetry is what makes the standard demanding.
0:00 / 0:00

Approval requires controlled human evidence that the drug produces a meaningful benefit relative to a real alternative, and the developer carries the burden of producing it.

Three things the evidence has to do

The evidence has to come from people, not models. It has to show a benefit that matters to patients, not just a change in a measurement. And it has to be strong enough that more than one well-run study points the same way.

A marker is not an outcome

Suppose an AI-designed molecule reliably lowers a protein that is elevated in a disease. That is a real result, and it may be a good sign. But regulators ask a different question: do patients live longer, feel better, or function more normally? A drug can move the marker and still fail to change the disease, because the marker may be a bystander rather than a cause. The gap between 'changed a measurement' and 'helped a patient' is where many candidates are lost.

The direction of proof matters. Regulators do not have to demonstrate harm to reject a drug; the developer has to demonstrate benefit to get it approved. This asymmetry is deliberate — it protects patients from treatments whose risks are unknown.

上一页1 / 4下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion